Clinical trials: Neuron Disease, Motor
Amyotrophic Lateral Sclerosis
Confirmation of Self-Reported Incident ALS Cases in the AARP-Diet and Health (AARP-DH) Cohort
Amyotrophic Lateral Sclerosis (ALS) is a rare but rapidly progressive neurological disease that often results in death within a few years after the diagnosis.
- Trial name
- NCT00377351
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Amyotrophic Lateral Sclerosis
Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting the central and peripheral motor neurons, characterized by the rapidity of its evolution (median survival of 3 years).
- Trial name
- NCT02874209
- Testing
- sodium MRI
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Amyotrophic Lateral Sclerosis, ALS
Study of miRNA Expression Pattern as Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis
The principal goal is to demonstrate that a specific pattern of microRNA (miRNA) expression can be correlated with the definite diagnostic of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- MIRSLA (NCT01992029)
- Testing
- Clinical evaluation, Muscular biopsy, Lumbar puncture
- Where
- France
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Neuromuscular Diseases, Cerebral Palsy
Rehabilitative Effect of the Use of a Gait Exoskeleton in Patients With Neuromuscular Disease or Cerebral Palsy
The purpose of this multicentric study is to assess the rehabilitative effect derived from the use of the ATLAS exoskeleton in children with neuromuscular diseases or cerebral palsy and with a level of less than 3 or less in the…
- Conditions
- Neuromuscular Diseases, Cerebral Palsy, SMA II
- Trial name
- NCT04813601
- Testing
- ATLAS 2030
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- MarsiBionics
Spinal Muscular Atrophy
Quality of Life and Participation of the Adult with Spinal Muscular Atrophy in France
Spinal muscular atrophy is a hereditary motorneuron disease caused by a mutation of the SMN1 gene, which is at the origin of a progressive limb and axial motor deficiency.
- Trial name
- QOLSMA (NCT05366465)
- Testing
- SMA adult patients
- Where
- 2 sites in France
- Volunteers
- 149 people
- Sponsor
- Hospices Civils de Lyon
Amyotrophic Lateral Sclerosis
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT03127267
- Testing
- Masitinib (6.0), Riluzole, Masitinib (4.5)
- Where
- 56 sites in United States, Belgium and 15 more
- Volunteers
- 495 people
- Sponsor
- AB Science
Amyotrophic Lateral Sclerosis
A Longitudinal Analysis of Biomarkers in Patients With ALS
Longitudinally collect biomarkers from patients with amyotrophic lateral sclerosis (ALS) and control participants in order to further elucidate both potential causes and treatments for ALS.
- Trial name
- LAB-PALS (NCT05309408)
- Testing
- Venipuncture, Lumbar Puncture
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Holy Cross Hospital, Florida
Amyotrophic Lateral Sclerosis
Analysis of Human ALS Tissues and Registry of ALS Patients
Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's Disease, is a progressive, terminal condition of muscle weakness that is associated with degeneration of neurons in the spinal cord and brain.
- Trial name
- NCT05067179
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Illinois Chicago
Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis
Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)
The goal of this two-part clinical trial is: 1) to evaluate the safety and efficacy of Debamestrocel - MSC-NTF (NurOwn) compared to placebo in participants with early symptomatic ALS and moderate disease presentation in ALS…
- Trial name
- NCT06973629
- Testing
- Debamestrocel - MSC-NTF (NurOwn)
- Where
- 15 sites in United States
- Volunteers
- 200 people
- Sponsor
- Brainstorm-Cell Therapeutics
Amyotrophic Lateral Sclerosis, Cannabis
EMERALD TRIAL Open Label Extension Study
EMERALD OLE trial is an open-label extension of the EMERALD trial. Long term tolerability and safety of the MediCabilis CBD oil has not been extensively studied.
- Conditions
- Amyotrophic Lateral Sclerosis, Cannabis, CBD, Motor Neuron Disease
- Trial name
- EMERALD-OLE (NCT04997954)
- Testing
- MediCabilis CBD oil
- Where
- Australia
- Volunteers
- 7 people
- Sponsor
- Gold Coast Hospital and Health Service
Neuromuscular Diseases
Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that causes the death of 30,000 affected individual every year.
- Trial name
- NCT03272802
- Testing
- Edaravone, Riluzole
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Isfahan University of Medical Sciences
Amyotrophic Lateral Sclerosis
Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome
The purpose of this study was to evaluate the efficacy and safety of low-dose IL-2 in the treatment of immunorelated ALS syndrome.
- Trial name
- NCT04952155
- Testing
- IL-2
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Peking University Third Hospital
Child Development, Upper Motor Neurone Lesion
Validity and Reliability of the PROprioception Measurement Tool (PROMT)
This project assesses the feasibility, reliability, and validity of the PROMT in children with a UMN lesion. The study questions are: is the newly developed PROMT a feasible, reliable, and valid tool to assess lower limb…
- Conditions
- Child Development, Upper Motor Neurone Lesion, Cerebral Palsy, Proprioceptive Disorders
- Trial name
- PROMT (NCT05405881)
- Testing
- Proprioception measurement tool
- Where
- Switzerland
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- University Children's Hospital, Zurich
Amyotrophic Lateral Sclerosis
Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)
This is a multi-center, 20-week study of inosine treatment. Study Objectives and Endpoints The primary objective of the study is to determine the safety and tolerability of oral administration of inosine (administered daily)…
- Trial name
- SURE-ALS2 (NCT03168711)
- Testing
- Inosine
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
Intravenous Injection of Adipose Derived Mesenchymal Stem Cell for ALS
Amyotrophic lateral sclerosis (ALS) is a lethal degenerative disorder that upper motor and lower motor neurons are destroyed in brain stem and spinal cord. Riluzole is the only therapeutic option now.
- Trial name
- NCT02492516
- Testing
- mesenchymal stem cells
- Where
- Iran
- Volunteers
- 19 people
- Sponsor
- Royan Institute
Spinal Muscular Atrophy Type 3
Whole Body Vibration Therapy in Children With Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) are one of the common physical disabilities in childhood. For SMA, progressive muscle weakness and early fatigue hamper the mobility of the sufferers.
- Trial name
- NCT03056144
- Testing
- whole body vibration therapy
- Where
- Hong Kong
- Volunteers
- 1 people
- Sponsor
- The Hong Kong Polytechnic University
ALS (Amyotrophic Lateral Sclerosis)
Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis
Open-label pilot study to determine the safety and tolerability of autologous CD4+ CD25+ regulatory T cells infusions with concomitant subcutaneous IL-2 injections taken 3 times per week in 3 participants with ALS.
- Trial name
- NCT03241784
- Testing
- Autologous T-regulatory lymphocytes, Interleukin-2
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- The Methodist Hospital Research Institute
Cerebral Cortex Dysfunction
Brain Function in Primary Lateral Sclerosis and Amyotrophic Lateral Sclerosis
This study will test whether primary lateral sclerosis (PLS) and amyotrophic lateral sclerosis (ALS) affect parts of the brain responsible for thinking, planning, memory and emotion.
- Trial name
- NCT00334516
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis (ALS)
Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis
This is a multicenter, Phase 2a, randomized, double-blind, placebo-controlled pilot study to assess the biological activity, safety and pharmacokinetics of PU-AD compared to placebo in ALS.
- Trial name
- ALS (NCT04505358)
- Testing
- PU-AD
- Sponsor
- Samus Therapeutics, Inc.
Amyotrophic Lateral Sclerosis
Trial of Early Noninvasive Ventilation for Amyotrophic Lateral Sclerosis (ALS)
The goal of this trial is to determine the feasibility of conducting a randomized, double-blind, placebo-controlled trial of nocturnal noninvasive positive pressure ventilation in persons with amyotrophic lateral sclerosis with…
- Trial name
- NCT00580593
- Testing
- BiPAP® S/T System
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Michigan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.